Search

In conclusion, this 10 y-FU update suggests that TILs markers that CD3, FOXP3 and CD8 IHC counts have predictive value by identifying patients with better sensitivity to R-maintenance. Ten years follow-up of PFS (months) according to CD3 IHC scores in the R-maintenance arm (A) and in the control (R-chemo without maintenance) arm (B) of the PRIMA trial. Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen. [Extracted from the article]

Summary: Follicular lymphomas (FLs) with MYC rearrangements (MYC‐R) and extra copies of MYC (MYC‐EC) are rare and the prognosis impact is uncertain. We conducted a retrospective study including 321 FL patients, among whom 259 (81%) had no 8q24 alterations and 62 (19%) were assigned to 8qAlt. Forty‐five cases were classified as MYC‐EC and six as MYC‐R. MYC‐R patients were significantly older (P = 0·008), had higher follicular lymphoma international prognostic index (FLIPI) stage (P = 0·05) and β2‐microglobulin (β2m; P = 0·05). Among patients treated with immuno‐chemotherapy, four presented a MYC‐R and 25 a MYC‐EC. Univariate analysis showed the absence of significant difference between MYC‐EC and normal MYC (MYC‐NL) regarding progression‐free survival (PFS; HR1·3; 95% CI [0·4–1·6]) and specific overall survival (SOS; HR 1·6; 95% CI [0·4–5·7]). Those results were compared to data from the PRIMA trial. This confirmed that MYC‐EC had no impact on PFS (P = 0·86) or SOS (P = 0·9). Conversely, MYC‐R was associated with a trend to inferior outcome regarding PFS (HR : 6·1; 95% CI [2·2–17·1]; P = 0·00026), lymphoma‐related death (SOS; HR 13·6; 95% CI [2·9–65]; P = 0·00014) and risk of transformation (transformation‐free survival (TFS); HR 82·7; 95% CI [14·8–463·4]; P < 0·0001). In conclusion, MYC‐EC has no prognostic impact in FL but MYC‐R FL tended to be associated with an increased risk of transformation and poorer outcome. [ABSTRACT FROM AUTHOR]